KLP Kapitalforvaltning AS Purchases 900 Shares of Mirum Pharmaceuticals, Inc. $MIRM

KLP Kapitalforvaltning AS grew its position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) by 13.4% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 7,600 shares of the company’s stock after acquiring an additional 900 shares during the quarter. KLP Kapitalforvaltning AS’s holdings in Mirum Pharmaceuticals were worth $387,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of MIRM. GAMMA Investing LLC lifted its position in shares of Mirum Pharmaceuticals by 4,555.0% in the 1st quarter. GAMMA Investing LLC now owns 5,586 shares of the company’s stock worth $252,000 after acquiring an additional 5,466 shares during the period. Wealth Enhancement Advisory Services LLC increased its stake in Mirum Pharmaceuticals by 2.1% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 16,685 shares of the company’s stock valued at $752,000 after acquiring an additional 339 shares during the period. Palumbo Wealth Management LLC bought a new position in shares of Mirum Pharmaceuticals during the 1st quarter worth approximately $242,000. KBC Group NV acquired a new stake in Mirum Pharmaceuticals in the 1st quarter valued at $89,000. Finally, Bank of New York Mellon Corp boosted its stake in Mirum Pharmaceuticals by 98.5% in the 1st quarter. Bank of New York Mellon Corp now owns 246,730 shares of the company’s stock valued at $11,115,000 after buying an additional 122,402 shares in the last quarter.

Mirum Pharmaceuticals Price Performance

Shares of MIRM stock opened at $73.53 on Monday. The stock has a 50-day moving average price of $72.58 and a 200 day moving average price of $55.86. The company has a quick ratio of 2.97, a current ratio of 3.13 and a debt-to-equity ratio of 1.21. The firm has a market cap of $3.69 billion, a price-to-earnings ratio of -60.77 and a beta of 0.81. Mirum Pharmaceuticals, Inc. has a 12 month low of $36.88 and a 12 month high of $78.54.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its earnings results on Wednesday, August 6th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.31) by $0.19. The company had revenue of $127.79 million during the quarter, compared to analyst estimates of $107.91 million. Mirum Pharmaceuticals had a negative return on equity of 24.76% and a negative net margin of 13.65%.The company’s revenue for the quarter was up 64.1% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.52) EPS. Research analysts expect that Mirum Pharmaceuticals, Inc. will post -1.43 EPS for the current year.

Insider Buying and Selling

In other news, CFO Eric Bjerkholt sold 9,578 shares of the business’s stock in a transaction dated Friday, September 12th. The stock was sold at an average price of $76.01, for a total transaction of $728,023.78. Following the completion of the transaction, the chief financial officer directly owned 39,945 shares in the company, valued at approximately $3,036,219.45. The trade was a 19.34% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Christopher Peetz sold 40,000 shares of the business’s stock in a transaction dated Monday, August 11th. The stock was sold at an average price of $62.00, for a total value of $2,480,000.00. Following the transaction, the chief executive officer owned 138,641 shares of the company’s stock, valued at $8,595,742. The trade was a 22.39% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 116,578 shares of company stock valued at $7,262,824 over the last 90 days. 22.87% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several analysts recently commented on MIRM shares. JMP Securities set a $81.00 price target on Mirum Pharmaceuticals and gave the company a “market outperform” rating in a research note on Thursday, August 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Mirum Pharmaceuticals in a research note on Wednesday, October 8th. Morgan Stanley boosted their price target on Mirum Pharmaceuticals from $75.00 to $81.00 and gave the company an “overweight” rating in a research note on Thursday. JPMorgan Chase & Co. boosted their price target on Mirum Pharmaceuticals from $53.00 to $77.00 and gave the company an “overweight” rating in a research note on Friday, September 12th. Finally, Cowen started coverage on Mirum Pharmaceuticals in a research note on Wednesday, September 24th. They issued a “buy” rating on the stock. Two research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $79.70.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.